Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Collaborators: Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C; Cori Analyticals; Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Centro de Bioequivalência; Faculty of Pharmaceutical Sciences of Ribeirão Preto - Bioequivalence Center; LabClin Laboratório Clínico; Laboratório de Patologia Clínica Dr. Franceschi Ltda.; Scentryphar Clinical Research
• Treatments: Candesartan; Candesartan cilexetil; Felodipine

Criteria

Inclusion Criteria:

• Healthy volunteers

• BMI > or = 19 and < or = 28 (Dietary Guidelines Advisory Committee, 2005)

Exclusion Criteria:

• Not healthy

• Chronic drug intake